Evidence map›Paper›PMID 38321107›Full record

ArticleLeukemia2024

Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.

James T England, Natasha Szuber, Shireen Sirhan, Tom Dunne, Sonia Cerquozzi, Madeleine Hill, Pierre J A Villeneuve, Jenny M Ho, Bekim Sadikovic, Pratibha Bhai and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Myeloproliferative Neoplasms and Cardiovascular Disease: A Review.Current treatment options in oncology · 2024
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

James T EnglandPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. james.england@mail.utoronto.ca.ORCID http://orcid.org/0000-0002-9692-1634
Natasha SzuberMaisonneuve-Rosemont Hospital, University of Montreal, Quebec, QC, Canada.
Shireen SirhanJewish General Hospital, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-4957-4307
Tom DunneDivision of Hematology, Newfoundland and Labrador Health Services, St. John's, NL, Canada.
Sonia CerquozziTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Madeleine HillThe Ottawa Hospital Research Institute, Ottawa, Ottawa, ON, Canada.ORCID http://orcid.org/0009-0008-0082-4559
Pierre J A VilleneuveThe Ottawa Hospital Research Institute, Ottawa, Ottawa, ON, Canada.ORCID http://orcid.org/0000-0002-0944-1721
Jenny M HoDivision of Hematology, Department of Medicine, Western University, London Health Sciences Centre, London, ON, Canada.
Bekim SadikovicDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.
Pratibha BhaiDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.
Nupur KrishnanRoyal Victoria Regional Health Center, Barrie, ON, Canada.
Sebastian DowhanikDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Chris HillisDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Jose-Mario Capo-ChichiDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Hubert TsuiDepartment of Hematopathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Verna CheungPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Karine GauthierPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Hassan SibaiPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Marta B DavidsonPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Aniket BankarPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Rouslan KotchetkovRoyal Victoria Regional Health Center, Barrie, ON, Canada.
Vikas GuptaPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1419-8607
Dawn MazePrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4598-9380
University of Toronto · CALondon Health Sciences Centre · CAMcMaster University · CARoyal Victoria Regional Health Centre · CASunnybrook Health Science Centre · CAHôpital Maisonneuve-Rosemont · CAJewish General Hospital · CANewfoundland and Labrador Centre for Applied Health Research · CAOttawa Hospital · CAUniversity Health Network · CAUniversity of Calgary · CAUniversity of Ottawa · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloproliferative neoplasms (MPNs) are a group of chronic hematologic malignancies that lead to morbidity and early mortality due to thrombotic complications and progression to acute leukemia. Clinical and mutational risk factors have been demonstrated to predict outcomes in patients with MPNs and are used commonly to guide therapeutic decisions, including allogenic stem cell transplant, in myelofibrosis. Adolescents and young adults (AYA, age ≤45 years) comprise less than 10% of all MPN patients and have unique clinical and therapeutic considerations. The prevalence and clinical impact of somatic mutations implicated in myeloid disease has not been extensively examined in this population. We conducted a retrospective review of patients evaluated at eight Canadian centers for MPN patients diagnosed at ≤45 years of age. In total, 609 patients were included in the study, with median overall survival of 36.8 years. Diagnosis of prefibrotic or overt PMF is associated with the lowest OS and highest risk of AP/BP transformation. Thrombotic complications (24%), including splanchnic circulation thrombosis (9%), were frequent in the cohort. Mutations in addition to those in JAK2/MPL/CALR are uncommon in the initial disease phase in our AYA population (12%); but our data indicate they may be predictive of transformation to post-ET/PV myelofibrosis.

Indexed as

Myeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisThrombocythemia, EssentialThrombosisAdolescentCalreticulinCanadaHumansJanus Kinase 2Middle AgedMutationYoung AdultCalreticulinJanus Kinase 2

Identifiers

PMID38321107
OpenAlexW4391559562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.